EGFR/HER2-IN-18
EGFR/HER2-IN-18 is a stable EGFR/HER2 dual inhibitor with IC50 values of 0.09 (EGFR) and 0.08 μM (HER2) respectively. EGFR/HER2-IN-18 exhibits broad-spectrum anti-cancer activity. EGFR/HER2-IN-18 induces MCF-7 cells apoptosis and inhibits the cell cycle. EGFR/HER2-IN-18 can be used for the study of breast cancer[1].
Product Specifications
UNSPSC
12352005
Target
EGFR
Related Pathways
JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Smiles
O=C(N/N=C1SC=C(C2=CC=C(C)C=C2)N/1C3=CC=C(Br)C=C3)C4=CC=CC(NC5=C6C(N(C7=CC=CC=C7)N=C6)=NC=N5)=C4
Molecular Formula
C34H25BrN8OS
Molecular Weight
673.58
References & Citations
[1]Salem IM, et al. Exploitation of novel pyrazolo[3,4-d]pyrimidine scaffold tethered to thiazole as potential EGFR/HER2 dual kinase inhibitor to overcome lapatinib resistant breast cancer: Design, synthesis, in silico docking and molecular dynamic simulation. Bioorg Chem. 2025 Jun 3;163:108671.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
ErbB2/HER2
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
